ACSL4 promotes prostate cancer growth, invasion and hormonal resistance

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44849-44863

  Wu, Xinyu ^a   Deng, Fangming ^a   Li, Yirong ^a   Daniels, Garrett ^a   Du, Xinxin ^a   Ren, Qinghu ^a   Wang, Jinhua ^a   Wang, Ling Hang ^a   Yang, Yang ^a   Zhang, Valerio ^a   Zhang, David ^b   Ye, Fei ^b   Melamed, Jonathan ^a   Monaco, Marie E ^a   Lee, Peng ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ACSL4; Androgen receptor; Castration resistance; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BETA CATENIN; BICALUTAMIDE; ENZYME; FATTY ACID; LONG CHAIN FATTY ACYL COA SYNTHETASE 4; UNCLASSIFIED DRUG; ANILIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AR PROTEIN, HUMAN; COENZYME A LIGASE; LONG-CHAIN-FATTY-ACID-COA LIGASE; NITRILE; TOLUENESULFONIC ACID DERIVATIVE; TUMOR MARKER;

ANDROGEN SYNTHESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FATTY ACID METABOLISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR INVASION; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; UPREGULATION;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COENZYME A LIGASES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, NUDE; NEOPLASM INVASIVENESS; NITRILES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOSYL COMPOUNDS; TRANSFECTION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84953439237     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6438     Document Type: Article

References (43)

1. Decker KF, Zheng D, He Y, Bowman T, Edwards JR and Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 2012; 40:10765-10779.
2. Wu X, Daniels G, Lee P and Monaco M. Lipid metabolism in prostate cancer. American Journal of Clinical and Experimental Urology. 2014; 2:111-120.
3. Soupene E and Kuypers FA. Mammalian Long-Chain Acyl-CoA Synthetases. Experimental Biology and Medicine. 2008; 233:507-521.
4. Lewin TMK, J-H.; Granger, D.A.; Vance, J. E.; Coleman,. A. Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently. Journal of Biological Chemistry. 2001; 276:24674-24679.
5. Lewin TMVH, C. G.; Krisans, S. K.; Coleman, R.A. Rat liver acyl-CoA synthetase 4 is a peripheral-membrane protein located in two distinct subcellular organelles, peroxisomes, and mitochondrial-associated membrane. Archives of Biochemistry and Biophysics. 2002; 404:263-270.
6. Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H and Yamamoto TT. A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. ProcNatlAcadSciUSA. 1997; 94:2880-2884.
7. Cao Y, Dave KB, Doan TP and Prescott SM. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Research. 2001; 61:8429-8434.
8. Liang YC, Wu CH, Chu JS, Wang CK, Hung LF, Wang YJ, Ho YS, Chang JG and Lin SY. Involvement of fatty acid-CoA ligase 4 in hepatocellular carcinoma growth: roles of cyclic AMP and p38 mitogen-activated protein kinase. World JGastroenterol. 2005; 11:2557-2563.
9. Monaco ME, Creighton CJ, Lee P, Zou X, Topham MK and Stafforini DM. Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity. Transl Oncol. 2010; 3:91-98.
10. Wu X, Li Y, Wang J, Wen X, Marcus MT, Daniels G, Zhang DY, Ye F, Wang LH, Du X, Adams S, Singh B, Zavadil J, Lee P and Monaco ME. Long Chain Fatty Acyl-CoA Synthetase 4 Is a Biomarker for and Mediator of Hormone Resistance in Human Breast Cancer. PLoS ONE. 2013; 8:e77060.
11. Maloberti PM, Duarte AB, Orlando UD, Pasqualini ME, Solano ÅR, Lopez-Otin C and Podesta EJ. Functional Interaction between Acyl-CoA Synthetase 4, Lipooxygenases and Cyclooxygenase-2 in the Aggressive Phenotype of Breast Cancer Cells. PLoS ONE. 2010; 5:e15540.
12. Orlando UD, Garona J, Ripoll GV, Maloberti PM, Solano AR, Avagnina A, Gomez DE, Alonso DF and Podesta EJ. The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipooxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target. PLoS ONE. 2012; 7:e40794.
13. Li Y, Li CX, Ye H, Chen F, Melamed J, Peng Y, Liu J, Wang Z, Tsou HC, Wei J, Walden P, Garabedian MJ and Lee P. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med. 2008; 12:2790-2798.
14. Vo BT, Morton D, Jr., Komaragiri S, Millena AC, Leath C and Khan SA. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 2013; 154:1768-1779.
15. Lee EC, Zhan P, Schallhom R, Packman K and Tenniswood M. Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ. 2003; 10:761-771.
16. Bai VU, Cifuentes E, Menon M, Barrack ER and Reddy GP. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol. 2005; 204:381-387.
17. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW and Ghosh PM. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene. 2007; 26:6061-6070.
18. Zhang DY, Ye F, Gao L, Liu X, Zhao X, Che Y, Wang H, Wang L, Wu J, Song D, Liu W, Xu H, Jiang B, Zhang W, Wang J and Lee P. Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div. 2009; 4:20.
19. Li Y, Zhang DY, Ren Q, Ye F, Zhao X, Daniels G, Wu X, Dynlacht B and Lee P. Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol Cell Biol. 2012; 32:2454-2466.
20. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV and Smans K. Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Progress in Lipid Research. 2013;
21. Wu X, Daniels G, Lee P and Monaco ME. Lipid metabolism in prostate cancer. American journal of clinical and experimental urology. 2014; 2:111-120.
22. Mashima T, Oh-hara T, Sato S, Mochizuki M, Sugimoto Y, Yamazaki K, Hamada J-i, Tada M, Moriuchi T, Ishikawa Y, Kato Y, Tomoda H, Yamori T and Tsuruo T. p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target. J Natl Cancer Inst. 2005; 97:765-777.
23. Qiao S and Tuohimaa P. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochemical and Biophysical Research Communications. 2004; 319:358-368.
24. Sung K, Park M, Hong S, Hwang S, Kwack M, Kim J and Kim M. Regulation of cell growth by fatty acid-CoA ligase 4 in human hepatocellular carcinoma cells. Experimental and Molecular Medicine. 2007; 39:477-482.
25. Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y, Tsuruo T and Seimiya H. Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Science. 2009; 100:1556-1562.
26. Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ and Mongan NP. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol. 2013; 7:555-566.
27. Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schule R and Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012; 131:2704-2709.
28. Hughes-Fulford M, Li C-F, Boonyaratanakornkit J and Sayyah S. Arachidonic Acid Activates Phosphatidylinositol 3-Kinase Signaling and Induces Gene Expression in Prostate Cancer. Cancer Research. 2006; 66:1427-1433.
29. Golej DL, Askari B, Kramer F, Barnhart S, Vivekanandan-Giri A, Pennathur S and Bornfeldt KE. Long-chain acyl-CoA synthetase 4 modulates prostaglandin E(2) release from human arterial smooth muscle cells. Journal of lipid research. 2011; 52:782-793.
30. Shaw MW, Ablin RJ, Ray P, Rubenstein M, Guinan PD and McKiel CF. Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol. 1985; 8:77-79.
31. Faas FH, Dang AQ, Pollard M, Hong XM, Fan K, Luckert PH and Schutz M. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol. 1996; 156:243-248.
32. Tjandrawinata RR, Dahiya R and Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 1997; 75:1111-1118.
33. Wang S, Yang Q, Fung KM and Lin HK. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol. 2008; 289:60-66.
34. Karantanos T, Corn PG and Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32:5501-5511.
35. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT and Chang C. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun. 2003; 305:462-469.
36. Edlind MP and Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014; 16:378-386.
37. Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, McLeod M, Li Y, Li CX, Feng A, Garabedian MJ, Wang Z, Roeder RG and Lee P. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A. 2008; 105:5236-5241.
38. Cai CQ, Peng Y, Buckley MT, Wei J, Chen F, Liebes L, Gerald WL, Pincus MR, Osman I and Lee P. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene. 2008; 27:3201-3210.
39. Wu X, Chen F, Sahin A, Albarracin C, Pei Z, Zou X, Singh B, Xu R, Daniels G, Li Y, Wei J, Blake M, Schneider RJ, Cowin P and Lee P. Distinct function of androgen receptor coactivator ARA70alpha and ARA70beta in mammary gland development, and in breast cancer. Breast Cancer Res Treat. 2011; 128:391-400.
40. Ye F, Che Y, McMillen E, Gorski J, Brodman D, Saw D, Jiang B and Zhang DY. The effect of Scutellaria baicalensis on the signaling network in hepatocellular carcinoma cells. Nutr Cancer. 2009; 61:530-537.
41. Epstein JI, Allsbrook WC, Jr., Amin MB and Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29:1228-1242.
42. Allred DC, Harvey JM, Berardo M and Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11:155-168.
43. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E and Huang F. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol. 2007; 8:R255.